Showing posts with label ABBV. Show all posts
Showing posts with label ABBV. Show all posts

Monday, February 27, 2017

ABBV too much debt for me

This article does not address AbbVie's debt to equity ratio of 5. M*
AbbVie Is Just A Hold Right Now $ABBV
Read more »

Thursday, October 29, 2015

ABBV good dividend and good call

Abbvie, symbol ABBV is part of the Dividend Machine stable of stocks.  We acquired ABBV as a spin off from Abbott Laboratories, symbol ABT. 

The Dividend Machine portfolios hold both stocks.  I personally sold off ABT and kept ABBV because most of the dividend yield came with the ABBV spin off.

However, I have been worried about ABBV because EPS (earnings per share) have been less than dividend paid out. That fundamental is changing and the four percent dividend yield has made ABBV worth keeping under the cloud of poor earnings.

I have sold many calls on ABBV while I have held it and today provides another nice opportunity.  See the table below for the call I sold today.

Disclosure: Long ABBV with calls

ABBV $62.73 and someone took it already.  Amazing 24 hour gain.   MM
Read more »

Thursday, September 24, 2015

I am trying to sell ABBV

I am trying to sell ABBV.   I describe why and how and discuss the risks of my strategy in this post. 

When the market swoons, I tend to ignore it unless I have a ton of cash around that needs investing.   I always have two years of routine expenses in cash, but I don’t have a “ton” of cash around right now.   Therefore, I am not a very active investor as the market dips.

I suggested to Alfred Ferol that the market, in its infinite over reactions, could drop to 10,000 and he asked me when I am going to sell.    

If I didn’t sell in 2008/2009, I certainly am not going to sell now.    This is the sixth time I have been through times like this:  1987, 1992, 1994, 2001, 2009, and now in 2015.    Income investors should never be in a situation where you have to sell something to pay your bills.    You need to structure your portfolio to provide enough income to supplement social security, pension, rental income and the like to meet your monthly expenses.   However, you can work your portfolio to create more income.

ABBV’s dividend better than parent ABT’s dividend.

While I am not a vigorous investor this week, I look for weaknesses in my portfolio to see if I should take action.   AbbVie, symbol ABBV, was a spin off from Abbott Labs, symbol ABT.   I sold ABT through covered calls quite a while ago because as a result of the split, ABBV retained the big cash flow and was paying about 4% whereas ABT was paying barely over 1%.   It made sense for an income investor to keep the higher cash flow.

ABBV’s D/E ratio is too high.

Today I looked at ABBV with the eye of a risk taker.   I measure risk by D/E ratio.   Any stock with a D/E ratio above 1 or above industry standard makes me nervous.   ABBV has been worth the risk because of the ample dividend and because it is volatile enough to command extra covered call income.  Plus even income investors appreciate a capital gain.

My gain in ABBV is about 119% even with the recent price decline from a high of $71.80.  ABBV’s yield is down to 3.55%.   The trigger is their D/E ratio which is 4.93.   This is way too high for me.   So I want to sell ABBV.   I am a little greedy have decided to sell a November covered call with a strike price very close to the trading price.  Strike prices that are close to the trading price, provide juicy income.  Plus, I should receive their October dividend, and the call premium.   Now I have to hope the call buyer will call away my stock.

ABBV Covered Call with Strike Price close to trading price.

The risk is I could be stuck with ABBV if the call buyer does not take my stock.   The risk is not huge as they continue to pay the dividend but the D/E ratio still makes me nervous.  If the stock is not called away, I will probably sell it out right.  However, the price could be lower than it is now.   The covered call table above presents the income opportunity from selling ABBV with a covered call strike price close to its trading price.

Work that portfolio.


Disclosure:  Long ABBV with calls

Read more »

Wednesday, June 17, 2015

Big Pharma provides big income ABBV

Big Pharma is about the only area of interest for me.   I see several calls on these stocks.  This post profiles a call on AbbVie.

AbbVie, symbol ABBV, is in two of my Dividend Machine Model Portfolios because Abbott Laboratories spun off ABBV.   All spin offs in my model portfolios stay in the portfolio.

ABBV would not be a Dividend Machine because the yield of 3% is less than the 3.5% that I require for 2015.  Moreover, EPS are less than the dividend paid out.   However, the “pipeline” is good and many think ABBV has growth potential.

ABBV has paid a dividend since the spin off beginning with a dividend of $.40 in January 2013.  If you own ABBV on the next expected ex-dividend date of July 11, 2015, you will receive a quarterly dividend of $.51.   That represents an annualized increase of 33%.

If you own ABBV as a result of the spin off, your cost basis is $25.62 but if you buy it today you will need to pay about $67.61.  This is quite a nice capital gain.   And today, you have a chance to sell a nice call.

See the table below for the call option details on a Sep. $72.50 call.


Disclosure:  Long ABBV with multiple calls June, July, and Sept.
Read more »